Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2022)
39 slides from Csl's shareholder meeting presentation, Oct 12, 2022
Slide 1: CSL Limited 2022 Annual General Meeting
For personal use only For immediate release 12 October 2022 CSL LIMITED 2022 ANNUAL GENERAL MEETING Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY). Please find attached the Chair and Chief Executive Officer addresses to shareholders ahead of CSL Limited’s Annual General Meeting, which will be hel
Slide 2: Chair Address at the CSL 2022 Annual General Meeting
Chair Address at the CSL 2022 Annual General Meeting Good morning Ladies and Gentlemen. Thank you for joining us today. There is a quorum present and I am delighted to For personal use only open the meeting. I would now like to introduce your Board of Directors and our Company Secretary: To my right
Slide 3: Chair address: operating results and growth
Although the worst of the pandemic appeared to be over, the external environment continued to throw up challenges. The omicron variant meant people were still falling ill and we saw staff absenteeism reach new heights across the world. At the same time, supply chain disruptions caused issues in sour
Slide 4: Chair address: facilities, R&D and Vifor acquisition
We will also soon open our new Plasma Fractionation Facility at our site in Broadmeadows. The investment ensures that Victoria continues to play an important role in the manufacture and supply of lifesaving medicines into Australia and other key markets, as well as secures advanced manufacturing job
Slide 5: Conclusion
Conclusion To conclude, I’d like to thank our shareholders for supporting our Company. The external environment will continue to present challenges, but I assure you we will meet these with the sense of purpose, and resilience, that have allowed us to perform strongly. For personal use only I’ll now
Slide 6: CEO and Managing Director Address
CEO and Managing Director Address at the CSL 2022 Annual General Meeting Thank you Brian and good morning to everyone and thank you for joining us today for CSL’s 2022 AGM. As I mentioned last year, I was anxious to return to Australia and support our For personal use only patients, our people and o
Slide 7: CEO address: plasma collections and FY22 overview
A constant topic since the emergence of COVID has been the growth rate of plasma collections. I’m pleased to say plasma collections have grown strongly, up 24% over the previous year which we anticipate will underpin strong sales growth this current financial year and we aim to continue this momentu
Slide 8: CEO address: CSL Seqirus and CSL Behring
• Our new plasmapheresis platform was approved during the year and is being rolled out in Financial Year 23. For personal use only And for CSL Seqirus: • Our influenza vaccines business CSL Seqirus, has delivered another exceptional performance. • US sales exceeding one billion dollars for the first
Slide 9: CEO address: plasma collections growth
Also, as I noted earlier, IG sales have been constrained by plasma collected last year - supply is the core limiting factor. A return to growth just doesn’t happen via one response effort, it requires a team in sync, driving and executing multiple innovative measures. For personal use only The CSL P
Slide 10: CEO address: Ig capacity and demand drivers
• Collecting plasma, albeit an important part of the process, is only one part of the jigsaw. We recently completed modules 5 and 6 at Bern which has added 8 million litres of additional IG capacity. Investment in these types of projects are costly, but absolutely necessary. For personal use only De
Slide 11: CEO address: CSL Seqirus operating highlights
The increase reflects an ongoing shift to CSL Seqirus’ differentiated products, particularly FLUAD, our adjuvanted product, which was up 41%. The northern hemisphere continues to be the dominant market for CSL Seqirus with EU and UK delivering particularly strong growth up 42%. For personal use only
Slide 12: CEO address: R&D pipeline
• We are excited to announce positive top line data for Garadacimab for HAE. The study met its primary and secondary endpoints and also demonstrated safety and tolerability • These results underscore our belief that garadacimab has the potential to become a transformative first-in-class therapy for
Slide 13: CEO address: sustainability
As Brian alluded to earlier, we recognise that the responsible management and efficient use of natural resources is key to the Company’s sustainable growth and our ability to deliver on our promise. As many of you will know, we communicated our sustainability strategy 12 months For personal use only
Slide 14: CEO address: outlook
committee, that I chair is creating a culture of accountability across the CSL enterprise. Outlook For personal use only Finally, let’s move our attention to the outlook for your business. Looking specifically at CSL Behring: • We see a continued improvement in plasma collections and that is expecte
Slide 15: CEO closing remarks
To close, I am absolutely certain that the fundamentals of our business are strong and the diversity of our pipeline is rich. This really sets up CSL to build on our track record of sustainable growth for years to come. With that, I will pass back to the Chair. For personal use only The Chair thanke
Slide 16: Welcome to CSL's 2022 Annual General Meeting
For personal use only CSL Limited Welcome to CSL’s 2022 Annual General Meeting Please ensure your mobile is on silent mode
Slide 17: Address from the Chair
Address from the Chair For personal use only Dr Brian McNamee AO Chair and Independent Non-Executive Director 2
Slide 18: Board of Directors and Company Secretary
Board of Directors and Company Secretary For personal use only Mr Paul Perreault, Mr Bruce Brook, Dr Megan Clark, Professor Andrew Cuthbertson, Ms Carolyn Hewson, Managing Director Non-executive Director Non-executive Director Executive Director Non-executive Director Professor Duncan Maskell, Ms Ma
Slide 19: Address from the Chair
Address from the Chair For personal use only Dr Brian McNamee AO Chair and Independent Non-Executive Director 4
Slide 20: The people and science of CSL save lives
The people and science of For personal use only CSL save lives. We develop and deliver innovative medicines that help people with serious and life-threatening conditions live full lives and protect the health of communities around the world. Danielle Living with PI 5
Slide 21: Operating Results
For personal use only 6 Operating Results
Slide 22: Growth
Growth For personal use only CSL Melbourne CSL Waltham, Boston United States. (photo: Gensler) 7
Slide 23: CSL Seqirus Holly Springs United States
The people and science of For personal use only CSL save lives. We develop and deliver innovative medicines that help people with serious and life-threatening conditions live full lives and protect the health of communities around the world. CSL Seqirus Holly Springs United States 8
Slide 24: CSL Plasma Fractionation Facility, Broadmeadows
The people and science of For personal use only CSL save lives. We develop and deliver innovative medicines that help people with serious and life-threatening conditions live full lives and protect the health of communities around the world. CSL Plasma Fractionation Facility Broadmeadows, Australia
Slide 25: Strong track record of revenue growth
Strong track record of revenue growth For personal use only Acquired Vifor Pharma 10,562 CSL Ltd Revenue (US$ million) Sale of JRH Biosciences 10,310 Acquired Aventis Behring 9,151 Sale of Biocor Acquired Zenyth Acquired Novartis 8,539 Animal Health influenza vaccine Acquired US business 7,915 CSL p
Slide 26: CSL Vifor
For personal use only 11 CSL Vifor
Slide 27: Sustainability Strategy
Sustainability Strategy For personal use only 12
Slide 28: Address from the CEO
For personal use only Address from the CEO Paul Perreault CEO & Managing Director 13
Slide 29: Important Notice and Disclaimer
For personal use only IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 30: FY22 Performance
FY22 Performance1 Revenue up 3% with net profit after tax down 6% For personal use only CSL Behring CSL Seqirus Performance • IDELVION® +20% • Seasonal influenza vaccines +16% in line with expectations • KCENTRA® +18% − FLUAD ® +41% As expected Ig and Albumin sales have − US sales >$1b for the first
Slide 31: CSL Behring
CSL Behring Revenue up 2%1 For personal use only Revenue Change1 Therapy $m % Revenue By Region1 Immunoglobulins 4,024 (3%) IVIG 2,511 (5%) SCIG 1,513 (0%) 1% (5%) Albumin 1,072 (1%) EU / UK 24% Haemophilia 1,166 8% Recombinants 759 16% North America US$8.6B 49% 2% Plasma 407 (4%) Asia Specialty 1,7
Slide 32: Plasma Collections
Plasma Collections Volume now exceeds pre-pandemic levels For personal use only 2020 2021 • Annual tax season drop 2022 • Pandemic and lockdowns begin • Vaccine momentum • Further initiatives Holiday • Stimulus burn-off Season Initiatives launched US fiscal stimulus JAN FEB MAR APR MAY JUN JULY AUG
Slide 33: CSL Behring: Well positioned for growth post COVID
CSL Behring Well positioned for growth post COVID For personal use only Investment In Ig Manufacturing Demand Collections Capacity • Collection centre fleet growth of • Ig yield improvement • Lead indicators of disease diagnosis >30% over COVID period initiatives returning • ~10% beds temporarily re
Slide 34: CSL Seqirus
CSL Seqirus1 Revenue up 13% For personal use only Revenue Change1 Revenue By Region1 Therapy $m % Egg Based 228 (25%) +16% Cell Culture 486 10% Seasonal 4% 7% Influenza Asia Adjuvanted Egg 885 41% vaccines Pacific 13% Other / In-licence 178 2% North US$2.0B America 57% Total Product Sales 1,777 15%
Slide 35: CSL Seqirus Operating Highlights
CSL Seqirus Operating Highlights For personal use only 135 million doses 65 + FLUAD ® years • Record volume distributed FY22 • CDC adopted ACIP’s recommendation to be a preferentially recommended seasonal vaccine option for adults aged 65+ years Holly Springs fill & finish completed and operational
Slide 36: R&D Highlights, Partnerships & Alliances
R&D Highlights Partnerships & Alliances For personal use only Immunology Cardiovascular & Metabolic • CSL, WEHI, & University of Melbourne secured State Government funding to create biotech start-up incubator in • Garadacimab (Anti-FXIIa) HAE • CSL112 (ApoA-1) CSL’s new global headquarters under – P
Slide 37: Sustainability Strategy
Sustainability Strategy Focused on 3 key pillars – For personal use only Environment, Social and Sustainable Workplace Carbon emissions reduction targets Scope 1 & 2 Scope 3 A reduction of 40% of absolute Scope 1 & 2 Ensure suppliers who contribute 67% of emissions against a baseline of the Scope 3
Slide 38: Outlook
Outlook1 Strong mid-term outlook as COVID recedes For personal use only Promising cluster of R&D programs nearing completion CSL Behring CSL Seqirus CSL Group • Strong plasma • Ongoing Northern • Continue to navigate collections and Ig Hemisphere challenging external growth anticipated demand for co
Slide 39: Thank you
For personal use only CSL Limited 2022 Annual General Meeting Thank you